user

PHARMACOKINETICS AND DISTRIBUTION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN RATS WITH RENAL DYSFUNCTION

被引：0
|
作者：
KINOSHITA, H [1 ]
OHISHI, N [1 ]
TOKURA, S [1 ]
OKAZAKI, A [1 ]
机构：
[1] CHUGAI PHARMACEUT CO LTD, DEV RES LABS, DRUG METAB LAB, TOKYO 171, JAPAN
来源：
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 1992年 / 42-1卷 / 05期
关键词：
ANTIANEMIC AGENTS; CAS; 11096-26-7; EPOCH(R); ERYTHROPOIETIN; RECOMBINANT HUMAN; RECOMBINANT HUMAN ERYTHROPOIETIN;
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Pharmacokinetics and distribution were studied following intravenous administration of recombinant human erythropoietin (rh-EPO, CAS 11096-26-7) to 5/6-nephrectomized rats. 5/6-Nephrectomy caused a significant decrease of total body clearance of rh-EPO. Renal function, therefore, is thought to affect the metabolism in extrarenal tissues. The metabolism of EPO might be indirectly associated with renal function. There were no differences of the concentration in the bone marrow and spleen between 5/6-nephrectomized rats and non-nephrectomized rats, suggesting that 5/6-nephrectomy does not cause a change in the affinity of rh-EPO for target tissues. Repeated administration of rh-EPO caused a slight reduction of the biological half-life in 5/6-nephrectomized rats as well as in non-nephrectomized rats, suggesting stimulation of a compensatory metabolism in extrarenal tissues.
引用
收藏
页码：682 / 686
页数：5
相关论文
共 50 条
  • [1] COMPARATIVE PHARMACOKINETICS AND DISTRIBUTION OF HUMAN URINARY ERYTHROPOIETIN AND RECOMBINANT-HUMAN-ERYTHROPOIETIN IN RATS
    KINOSHITA, H
    OHISHI, N
    KATO, M
    TOKURA, S
    OKAZAKI, A
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 1991, 41-2 (09): : 1004 - 1007
  • [2] PHARMACOKINETICS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN
    SINYUKHIN, VN
    STETSYUK, YA
    LOVCHINSKY, YV
    LEBEDEV, SV
    YARMOLINSKY, IS
    LYAKHOV, VV
    TERAPEVTICHESKII ARKHIV, 1994, 66 (08) : 60 - 62
  • [3] PHARMACOKINETICS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN CHILDREN WITH RENAL-FAILURE
    EVANS, JHC
    BROCKLEBANK, JT
    BOWMER, CJ
    NG, PC
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1991, 6 (10) : 709 - 714
  • [4] PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN
    BROCKMOLLER, J
    KOCHLING, J
    SCIGALLA, P
    WEBER, W
    ROOTS, I
    NEUMAYER, HH
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (06) : 2391 - 2392
  • [5] CLINICAL PHARMACOKINETICS OF EPOETIN (RECOMBINANT-HUMAN-ERYTHROPOIETIN)
    MACDOUGALL, IC
    ROBERTS, DE
    COLES, GA
    WILLIAMS, JD
    CLINICAL PHARMACOKINETICS, 1991, 20 (02) : 99 - 113
  • [6] PHARMACOKINETICS OF INTRAVENOUS RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS WITH CHRONIC-RENAL-FAILURE
    SALMONSON, T
    DANIELSON, BG
    GRAHNEN, A
    WIKSTROM, B
    JOURNAL OF INTERNAL MEDICINE, 1990, 228 (01) : 53 - 57
  • [7] TREATING RENAL ANEMIA WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    ROSS, CN
    REES, AJ
    BRITISH MEDICAL JOURNAL, 1990, 300 (6731): : 1078 - 1079
  • [8] RECOMBINANT-HUMAN-ERYTHROPOIETIN AND RENAL-TRANSPLANTATION
    KEOWN, PA
    SEMINARS IN NEPHROLOGY, 1990, 10 (02) : 52 - 58
  • [9] PHARMACOKINETICS AND DISTRIBUTION OF RECOMBINANT ERYTHROPOIETIN IN RATS
    KINOSHITA, H
    OHISHI, N
    KATO, M
    TOKURA, S
    OKAZAKI, A
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 1992, 42-1 (02): : 174 - 178
  • [10] PHARMACOKINETICS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN APPLIED SUBCUTANEOUSLY TO CHILDREN WITH CHRONIC-RENAL-FAILURE
    BRAUN, A
    DING, R
    SEIDEL, C
    FIES, T
    KURTZ, A
    SCHARER, K
    PEDIATRIC NEPHROLOGY, 1993, 7 (01) : 61 - 64
12345